Tuesday , February 20 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 19)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

August 6, 2016

This past week, one of my favorite patients came back from a visit to Mississippi and was distraught. This patient was diagnosed with diabetes 6 years ago, and after significant weight loss he had to be placed on insulin. Being one of those people who believed he could “cure” his …

Read More »

August 2, 2016

We have all used the phrase “if you build it, they will come,” and when it comes to glucose monitoring systems and interconnectivity, it seems that every manufacturer has a belief that this is true. When Steve and Joy were at the recent ADA Scientific Sessions there were over 20 …

Read More »

July 30, 2016

There is an old saying in medicine: “above all do no harm.” This term often comes into play when our patients ask us about nutritional products for diabetes and other diseases, as well as when someone tells us about the greatest new exercise program to “cure” diabetes. This week we …

Read More »

July 26, 2016

There are various hormones, neurotransmitters, nucleotides, and fatty acids in the pancreas that affect insulin production and secretion. Sorting all these factors out, and how we might possibly affect glucose control by mimicking  some of these compounds, has opened up new avenues of treatment. GLP-1 agonists are just one example. This week in our …

Read More »

July 23, 2016

For many years, we have used finger sticks as the standard for diagnosis and management of diabetes. I can remember inviting patients to come to the pharmacy for a “diabetes day” where we offered free testing, and we would often find patients with elevated glucose levels. We would also spend …

Read More »

July 21, 2016

The dust has settled from the ADA scientific sessions in New Orleans and we have had time to look at what we learned about SGLT-2 Inhibitors. There were at least 40 posters on how they work and what they can do, but there was not a whole lot about clinical use. …

Read More »

Over the last 7 years we have heard all about the benefits of GLP-1 analogs. One of the benefits that is often touted is the increase in first phase insulin release. In simple terms, we define this as “the quick release of insulin at the first bite of food,” but …

Read More »

July 16, 2016

When I was was doing a lot of diabetes management and pump starts, U-500 was always a fear causer for many medical professionals. Part of this came from problems with the conversion from a U-100 dose to an equivalent U-500 dose. Even though you simply divided the unit dose by …

Read More »

July 12, 2016

Pyruvate cycling pathway is a term I have not heard in many years. When I was in pharmacy school, I remember our Medicinal Chemistry professor posting a slide on the overhead, and telling us if we learned this by the end of the semester we would pass the class. Although …

Read More »

July 9, 2016

Sixteen years ago when Steve and I started this newsletter, we were sending it out to 30 pharmacists we knew. As more and more of you started subscribing and sharing our site and newsletter with others, I would sometimes sit at my desk in awe of what we had accomplished …

Read More »